Cubist Pharmaceuticals Inc. (Nasdaq: CBST) has signed an exclusive option to acquire Illumigen Biosciences Inc., a Seattle-based drug developer whose lead product is an interferon replacement product for the treatment of Hepatitis C infections. Cubist would pay $4.7 million on the option, plus another $1 million for an IND-enabling study on Illumigen's lead compound. Illumigen has raised around $6 million in VC funding from Pacific Horizon Ventures and Ventures West. www.cubist.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.